Swedish Orphan Biovitrum AB (publ)
STO:SOBI
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
239.4
346.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Swedish Orphan Biovitrum AB (publ)
Wall Street
Price Targets
SOBI Price Targets Summary
Swedish Orphan Biovitrum AB (publ)
According to Wall Street analysts, the average 1-year price target for
SOBI
is 355.42 SEK
with a low forecast of 252.5 SEK and a high forecast of 577.5 SEK.
Operating Income
Forecast
Operating Income Estimate
Swedish Orphan Biovitrum AB (publ)
For the last 8 years the
compound annual growth rate for
Swedish Orphan Biovitrum AB (publ)'s operating income is
54%.
The projected
CAGR
for the next 3 years is
29%.
Net Income
Forecast
Net Income Estimate
Swedish Orphan Biovitrum AB (publ)
For the last 8 years the
compound annual growth rate for
Swedish Orphan Biovitrum AB (publ)'s net income is
57%.
The projected
CAGR
for the next 3 years is
46%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is SOBI's stock price target?
Price Target
355.42
SEK
According to Wall Street analysts, the average 1-year price target for
SOBI
is 355.42 SEK
with a low forecast of 252.5 SEK and a high forecast of 577.5 SEK.
What is Swedish Orphan Biovitrum AB (publ)'s Revenue forecast?
Projected CAGR
13%
For the last 8 years the
compound annual growth rate for
Swedish Orphan Biovitrum AB (publ)'s revenue is
27%.
The projected
CAGR
for the next 3 years is
13%.
What is Swedish Orphan Biovitrum AB (publ)'s Operating Income forecast?
Projected CAGR
29%
For the last 8 years the
compound annual growth rate for
Swedish Orphan Biovitrum AB (publ)'s operating income is
54%.
The projected
CAGR
for the next 3 years is
29%.
What is Swedish Orphan Biovitrum AB (publ)'s Net Income forecast?
Projected CAGR
46%
For the last 8 years the
compound annual growth rate for
Swedish Orphan Biovitrum AB (publ)'s net income is
57%.
The projected
CAGR
for the next 3 years is
46%.
You don't have any saved screeners yet
